Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study

Therapeutic Drug Monitoring
Katharine R DekkerMichael A Barras

Abstract

To investigate the compliance of prescribers with the state-wide Queensland Health (QH) guidelines for dosing and monitoring of enoxaparin, and to examine the effect that compliance has on the patients' length of stay (LOS) in hospital. A 4-week retrospective study of consecutive inpatients who were administered enoxaparin for the treatment of an embolic disease. Data collected included influential patient demographics such as weight, renal function; details of antifactor Xa (aXa) monitoring, and patient LOS. All dosing and monitoring for each patient was compared to the current QH guidelines for enoxaparin usage; a multidisciplinary consensus document. The reasons for noncompliance were quantified and explored. A total of 67 inpatients were recruited. The median (range) age, weight, and creatinine clearance of patients were 66 years (18-92), 78.5 kg (47.6-182), and 64 mL/min (16-180), respectively. Only 20 (30%) patients received enoxaparin in compliance with QH guidelines, leaving 47 (70%) noncompliant. The median (range) LOS was 7 (2-58) days for the compliant group versus 15 days (2-101) for the noncompliant (P = 0.06, Mann-Whitney U test). A total of 10 (15%) patients were monitored for aXa; none of whom were monitored cor...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jan 22, 1997·JAMA : the Journal of the American Medical Association·D C ClassenJ P Burke
Oct 3, 2002·The Medical Journal of Australia·John W Eikelboom, Graeme J Hankey
Jul 10, 2003·British Journal of Clinical Pharmacology·Bruce Green, Stephen B Duffull
Oct 9, 2003·JAMA : the Journal of the American Medical Association·Chunliu Zhan, Marlene R Miller
Oct 2, 2004·American Heart Journal·Michael W Kruse, Jeremy J Lee
Mar 9, 2005·British Journal of Clinical Pharmacology·B GreenJ Atherton
Oct 12, 2007·Clinical Pharmacology and Therapeutics·M A BarrasB Green
Jun 25, 2010·British Journal of Clinical Pharmacology·Michael A BarrasBruce Green
Aug 21, 2012·The Medical Journal of Australia·David W JohnsonUNKNOWN Australasian Creatinine Consensus Working Group
Nov 7, 2012·Archives of Internal Medicine·Douglas D DeCarolisGerhard J Johnson

❮ Previous
Next ❯

Citations

Jun 21, 2018·Frontiers in Pharmacology·Rahul P PatelGregory M Peterson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The International Journal of Angiology : Official Publication of the International College of Angiology, Inc
Ashish Anil SuleEarnest Arul
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
Elizabeth W McCormickJill A Morgan
© 2022 Meta ULC. All rights reserved